Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Qualified Opinion who wrote (5115)	11/15/2003 8:13:26 PM
From: Cacaito	Read Replies (1) \| Respond to of 10345

Dec 03 Surprise! Complete AZ (halted trial) data should be ready, if it match the German subgroup results (30 subjects), the whole group was 300 plus, most received the vaccine, ratio was like 3 to 1). The full clinical data will (if it match the the subgroup results) prove that the vaccine is effective, only safety to be determined for the conjugate vaccine and/or the mab. Elan could file Antegren for Crohn's in a rolling NDA, with the full maintnance trial ongoing and pending. Elan could file Antegren for MS with the 1 year period in a rolling NDA, and the full two years period ongoing and pending. IF Antegren for MS major hurdle is overcome, whether it does impact dissability scores favorably at 1 year (it did but not statistically significant at 6 month in the phase II), if it does then approval is certain earlier. Biogen vs Wyeth, $12 to $15 for Elan, $18 should be fine, is paper money anyway !!!